Allergy Therapeutics PLC
LSE:AGY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Skane mollan AB
STO:SKMO
|
SE |
|
I
|
IOI Properties Group Bhd
KLSE:IOIPG
|
MY |
Allergy Therapeutics PLC
Research & Development
Allergy Therapeutics PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Research & Development
-£15.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-17%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Research & Development
-£6.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Research & Development
-$13.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-9%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Research & Development
-$151m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-15%
|
|
|
Animalcare Group PLC
LSE:ANCR
|
Research & Development
-£2.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-32%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Allergy Therapeutics PLC
Glance View
Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.
See Also
What is Allergy Therapeutics PLC's Research & Development?
Research & Development
-15.4m
GBP
Based on the financial report for Jun 30, 2025, Allergy Therapeutics PLC's Research & Development amounts to -15.4m GBP.
What is Allergy Therapeutics PLC's Research & Development growth rate?
Research & Development CAGR 10Y
-17%
Over the last year, the Research & Development growth was 33%. The average annual Research & Development growth rates for Allergy Therapeutics PLC have been 1% over the past three years , -11% over the past five years , and -17% over the past ten years .
